Geode Capital Management LLC Acquires 88,061 Shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR)

Geode Capital Management LLC raised its stake in shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR - Free Report) by 14.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 685,746 shares of the company's stock after buying an additional 88,061 shares during the quarter. Geode Capital Management LLC owned about 1.85% of Lifecore Biomedical worth $5,097,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in LFCR. ARS Investment Partners LLC purchased a new position in Lifecore Biomedical in the 4th quarter worth $74,000. Prudential Financial Inc. purchased a new position in shares of Lifecore Biomedical during the fourth quarter worth approximately $95,000. Barclays PLC boosted its position in Lifecore Biomedical by 301.7% during the 3rd quarter. Barclays PLC now owns 29,944 shares of the company's stock valued at $147,000 after acquiring an additional 22,489 shares in the last quarter. Lepercq Multi Asset Fund acquired a new position in Lifecore Biomedical during the fourth quarter worth $169,000. Finally, Jane Street Group LLC lifted its stake in shares of Lifecore Biomedical by 101.7% in the third quarter. Jane Street Group LLC now owns 36,246 shares of the company's stock worth $179,000 after buying an additional 18,277 shares in the last quarter. 83.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Stephens reaffirmed an "equal weight" rating and set a $6.00 target price on shares of Lifecore Biomedical in a research note on Friday, January 3rd.

Lifecore Biomedical Stock Performance

Shares of Lifecore Biomedical stock traded down $0.02 during trading on Thursday, hitting $6.75. 69,470 shares of the stock were exchanged, compared to its average volume of 229,394. The company has a debt-to-equity ratio of 9.21, a quick ratio of 1.21 and a current ratio of 2.32. Lifecore Biomedical, Inc. has a 12 month low of $3.68 and a 12 month high of $7.99. The stock's fifty day moving average is $6.24 and its 200 day moving average is $6.39. The stock has a market cap of $249.73 million, a PE ratio of -11.90 and a beta of 0.80.

Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) last announced its earnings results on Thursday, April 3rd. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.05). Lifecore Biomedical had a negative net margin of 12.52% and a negative return on equity of 315.23%. The company had revenue of $35.15 million for the quarter, compared to analysts' expectations of $33.23 million. As a group, sell-side analysts anticipate that Lifecore Biomedical, Inc. will post -0.91 EPS for the current year.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.